Loading...
ILM1 logo

Medios AGXTRA:ILM1 Stock Report

Market Cap €357.6m
Share Price
€14.02
n/a
1Y16.1%
7D2.3%
Portfolio Value
​
View

Medios AG

XTRA:ILM1 Stock Report

Market Cap: €357.6m

Medios (ILM1) Stock Overview

Supplies specialty pharmaceutical drugs primarily in Germany. More details

ILM1 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance5/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 57.3% below our estimate of its fair value

Earnings are forecast to grow 25.46% per year

Earnings grew by 71.1% over the past year

Analysts in good agreement that stock price will rise by 66.9%

Risk Analysis

No risks detected for ILM1 from our risk checks.

ILM1 Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

ILM1 logo
Medios

Integration Risks And Regulation Will Slow Progress Yet Yield Recovery

Key Takeaways Integration challenges and regulatory pressures may limit margin improvement and revenue growth, despite efforts to expand in higher-value specialty markets and enhance operational efficiency. Demographic trends and healthcare budget constraints could increase competition and pricing pressure, challenging Medios' ability to sustain top-line and earnings growth.
View narrative
€18
FV
22.1% undervalued intrinsic discount
2.57%
Revenue growth p.a.
12
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ILM1 logo
Medios

Advanced Therapies And European Integration Will Redefine Healthcare Delivery

Key Takeaways Expansion into advanced therapies and personalized medicine positions Medios for higher margins and sustained long-term growth through individualized treatments. Integration of Ceban and investment in digital tools enhance operational efficiency, supporting international expansion and scalable revenue opportunities.
View narrative
€24.5
FV
42.8% undervalued intrinsic discount
2.72%
Revenue growth p.a.
26
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
ILM1 logo
Medios

Aging European Populations And Advanced Therapies Will Energize Healthcare

Key Takeaways Accelerated synergy realization from recent integration and advanced therapy focus positions Medios for stronger revenue, margin, and international growth than current forecasts suggest. Strategic investments and balance sheet strength enable Medios to pursue acquisitions and efficiency, capturing sustained growth opportunities in a rapidly consolidating specialty pharma market.
View narrative
€27
FV
48.1% undervalued intrinsic discount
3.06%
Revenue growth p.a.
5
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
View Stock Community

Medios AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Medios
Historical stock prices
Current Share Price€14.02
52 Week High€16.06
52 Week Low€9.98
Beta1.04
1 Month Change1.74%
3 Month Change3.39%
1 Year Change16.06%
3 Year Change-21.06%
5 Year Change-62.01%
Change since IPO79.77%

Recent News & Updates

Market Still Lacking Some Conviction On Medios AG (ETR:ILM1)

Oct 08
Market Still Lacking Some Conviction On Medios AG (ETR:ILM1)

Is Medios (ETR:ILM1) Using Too Much Debt?

Aug 15
Is Medios (ETR:ILM1) Using Too Much Debt?

Recent updates

Market Still Lacking Some Conviction On Medios AG (ETR:ILM1)

Oct 08
Market Still Lacking Some Conviction On Medios AG (ETR:ILM1)

Is Medios (ETR:ILM1) Using Too Much Debt?

Aug 15
Is Medios (ETR:ILM1) Using Too Much Debt?

Shareholders Will Probably Hold Off On Increasing Medios AG's (ETR:ILM1) CEO Compensation For The Time Being

May 21
Shareholders Will Probably Hold Off On Increasing Medios AG's (ETR:ILM1) CEO Compensation For The Time Being

There May Be Some Bright Spots In Medios' (ETR:ILM1) Earnings

Apr 02
There May Be Some Bright Spots In Medios' (ETR:ILM1) Earnings

Medios AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 28
Medios AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
User avatar

Expansion Into Advanced Therapies Will Diversify Revenue Streams And Strengthen Market Position

Integration of Ceban drives synergies, enhancing revenue and net margins through cross-selling and economies of scale.

Is It Time To Consider Buying Medios AG (ETR:ILM1)?

Feb 18
Is It Time To Consider Buying Medios AG (ETR:ILM1)?

Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

May 21
Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly

Aug 19
Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly

Is Medios AG (ETR:ILM1) Trading At A 39% Discount?

Mar 02
Is Medios AG (ETR:ILM1) Trading At A 39% Discount?

Is Medios (ETR:ILM1) Using Too Much Debt?

Nov 27
Is Medios (ETR:ILM1) Using Too Much Debt?

Is It Too Late To Consider Buying Medios AG (ETR:ILM1)?

Oct 21
Is It Too Late To Consider Buying Medios AG (ETR:ILM1)?

Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly

Aug 12
Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly

Is Now The Time To Look At Buying Medios AG (ETR:ILM1)?

Jul 07
Is Now The Time To Look At Buying Medios AG (ETR:ILM1)?

Is Medios (ETR:ILM1) Using Too Much Debt?

Apr 28
Is Medios (ETR:ILM1) Using Too Much Debt?

Here's Why I Think Medios (ETR:ILM1) Is An Interesting Stock

Mar 07
Here's Why I Think Medios (ETR:ILM1) Is An Interesting Stock

What Does Medios AG's (ETR:ILM1) Share Price Indicate?

Feb 08
What Does Medios AG's (ETR:ILM1) Share Price Indicate?

Medios (ETR:ILM1) Has A Pretty Healthy Balance Sheet

Nov 29
Medios (ETR:ILM1) Has A Pretty Healthy Balance Sheet

Is There Now An Opportunity In Medios AG (ETR:ILM1)?

Oct 02
Is There Now An Opportunity In Medios AG (ETR:ILM1)?

Medios AG's (ETR:ILM1) Intrinsic Value Is Potentially 35% Above Its Share Price

Jun 18
Medios AG's (ETR:ILM1) Intrinsic Value Is Potentially 35% Above Its Share Price

What Is Medios AG's (ETR:ILM1) Share Price Doing?

May 25
What Is Medios AG's (ETR:ILM1) Share Price Doing?

Are Medios' (ETR:ILM1) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 17
Are Medios' (ETR:ILM1) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Bullish: Analysts Just Made A Significant Upgrade To Their Medios AG (ETR:ILM1) Forecasts

Jan 21
Bullish: Analysts Just Made A Significant Upgrade To Their Medios AG (ETR:ILM1) Forecasts

What You Need To Know About Medios AG's (ETR:ILM1) Investor Composition

Jan 19
What You Need To Know About Medios AG's (ETR:ILM1) Investor Composition

Is It Time To Consider Buying Medios AG (ETR:ILM1)?

Dec 24
Is It Time To Consider Buying Medios AG (ETR:ILM1)?

Analysts Are Betting On Medios AG (ETR:ILM1) With A Big Upgrade This Week

Dec 09
Analysts Are Betting On Medios AG (ETR:ILM1) With A Big Upgrade This Week

The Medios (ETR:ILM1) Share Price Is Up 128% And Shareholders Are Boasting About It

Dec 08
The Medios (ETR:ILM1) Share Price Is Up 128% And Shareholders Are Boasting About It

Shareholder Returns

ILM1DE HealthcareDE Market
7D2.3%0.7%0.08%
1Y16.1%23.6%14.1%

Return vs Industry: ILM1 underperformed the German Healthcare industry which returned 22.8% over the past year.

Return vs Market: ILM1 exceeded the German Market which returned 13.9% over the past year.

Price Volatility

Is ILM1's price volatile compared to industry and market?
ILM1 volatility
ILM1 Average Weekly Movement6.6%
Healthcare Industry Average Movement6.7%
Market Average Movement5.1%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.5%

Stable Share Price: ILM1 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: ILM1's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a999Matthias Gaertnerwww.medios.ag

Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. The company operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies.

Medios AG Fundamentals Summary

How do Medios's earnings and revenue compare to its market cap?
ILM1 fundamental statistics
Market cap€357.59m
Earnings (TTM)€22.03m
Revenue (TTM)€2.01b
16.2x
P/E Ratio
0.2x
P/S Ratio

Is ILM1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ILM1 income statement (TTM)
Revenue€2.01b
Cost of Revenue€1.82b
Gross Profit€193.00m
Other Expenses€170.97m
Earnings€22.03m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Mar 26, 2026

Earnings per share (EPS)0.86
Gross Margin9.59%
Net Profit Margin1.09%
Debt/Equity Ratio38.2%

How did ILM1 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/22 09:03
End of Day Share Price 2025/12/22 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medios AG is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael HeiderBerenberg
Samuel EnglandBerenberg
Charlotte FriedrichsBerenberg